by: Parent Project Muscular Dystrophy
On October 4th, Sarepta Therapeutics announced the initiation, in partnership with Roche, of a pivotal study of SRP-9001-301 (rAAVrh74.MHCK7.micro-dystrophin) also known as EMBARK.
Simultaneously, the company announced plans to host a community webinar with PPMD on Wednesday, Oct. 13, 2021, at 3:00 pm Eastern Time and a separate SRP-9001 Micro-dystrophin R&D Day on Monday, Oct. 11, 2021, at 8:30 am Eastern Time, which can be accessed here.
PPMD would like to remind everyone that the primary audience for R&D Day is the investor community and may include information on the company’s entire portfolio beyond Duchenne. While the public may attend, we urge attendees to keep the target audience in mind.
We understand that in this time full of hope, there is also anxiety and confusion for many in our community. We ask that you compile your questions and send them to PPMD in advance of the community webinar on the 13th by emailing them to info@parentprojectmd.org, with the subject line EMBARK.
